ADP-ribosylation factor (Arf) GTPase-activating protein (GAP) with coiled-coil, ankyrin repeat and PH domains 1 (ACAP1) is an Arf6 GAP that regulates membrane trafficking and is critical for the migratory potential of cells. However, the roles of ACAP1 have not been fully explored and its association with clinicopathological features in ovarian cancer is still unknown. In this study, we systematically analyzed multiple databases, including TISIDB, Tumor Immune Estimation Resource (TIMER2.0), Gene Expression Omnibus (GEO), CORTECON, Kaplan–Meier Plotter and LinkedOmics platforms to reveal the clinical significance and function of ACAP1 in ovarian cancer. We found that the expression of ACAP1 was upregulated in ovarian cancer and high ACAP1 expression predicted poor prognosis. Our data demonstrated that the expression and methylation status of ACAP1 were strongly correlated with immune infiltration levels, immunomodulators, and chemokines. Gene set enrichment analysis (GSEA) analysis also showed that the mechanism of ACAP1 in regulating ovarian cancer was related to a variety of immune-related pathways. In addition, we also revealed that the expression of ACAP1 was altered during cell differentiation and associated with cancer cell stemness markers. Our study highlights the clinical significance of ACAP1 in ovarian cancer and provides insight into the novel function of ACAP1 in regulation of tumor immune microenvironment and cancer cell stemness.
Get full access to this article
View all access options for this article.
References
1.
AhmedN., EscalonaR., LeungD., ChanE., and KannourakisG. (2018). Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. Semin Cancer Biol, 53, 265–281.
2.
BaatenB.J., LiC.R., DeiroM.F., LinM.M., LintonP.J., and BradleyL.M. (2010). CD44 regulates survival and memory development in Th1 cells. Immunity, 32, 104–115.
3.
BrayF., FerlayJ., SoerjomataramI., SiegelR.L., TorreL.A., and JemalA. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394–424.
4.
ChanC., PangX., ZhangY., NiuT., YangS., ZhaoD., et al. (2019). ACAP1 assembles into an unusual protein lattice for membrane deformation through multiple stage. PLoS Comput Biol 15,e1007081.
5.
ChenP.W., LuoR., JianX., and RandazzoP.A. (2014). The Arf6 GTPase-activating proteins ARAP2 and ACAP1 define distinct endosomal compartments that regulate integrin α5β1 traffic. J Biol Chem, 289, 30237–30248.
6.
ChristofiT., BaritakiS., FalzoneL., LibraM., and ZaravinosA. (2019). Current perspectives in cancer immunotherapy. Cancers (Basel) 11,1472.
7.
ClarkeM.F. (2019). Clinical and therapeutic implications of cancer stem cells. N Engl J Med, 380, 2237–2245.
8.
CuriglianoG. (2018). Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors. Semin Cancer Biol, 52, 253–258.
9.
DeatonA.M., and BirdA. (2011). CpG islands and the regulation of transcription. Genes Dev, 25, 1010–1022.
10.
DijkgraafE.M., SantegoetsS.J., ReynersA.K., GoedemansR., WoutersM.C., KenterG.G., et al. (2015). A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. Ann Oncol, 26, 2141–2149.
11.
DoH.T.T., LeeC.H., and ChoJ. (2020). Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers. Cancers (Basel) 12,287.
12.
DoushY., SuraniA.A., Navarro-CorcueraA., McArdleS., BillettE.E., and Montiel-DuarteC. (2019). SP1 and RARα regulate AGAP2 expression in cancer. Sci Rep 9,390.
13.
FeketeJ.T., Ősz, Á., PeteI., NagyG.R., VereczkeyI., and GyőrffyB. (2020). Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients. Gynecol Oncol, 156, 654–661.
14.
FujiwaraK., HasegawaK., and NagaoS. (2019). Landscape of systemic therapy for ovarian cancer in 2019: primary therapy. Cancer, 125, 4582–4586.
15.
GhisoniE., ImbimboM., ZimmermannS., and ValabregaG. (2019). Ovarian cancer immunotherapy: turning up the heat. Int J Mol Sci 20,2927.
16.
GreenD.S., NunesA.T., David-OcampoV., EkwedeI.B., HoustonN.D., HighfillS.L., et al. (2018). A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer. J Transl Med 16,196.
17.
HänzelmannS., CasteloR., and GuinneyJ. (2013). GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14,7.
18.
HashimotoS., FurukawaS., HashimotoA., TsutahoA., FukaoA., SakamuraY., et al. (2019). ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer. Proc Natl Acad Sci U S A, 116, 17450–17459.
19.
JacksonT.R., BrownF.D., NieZ., MiuraK., ForoniL., SunJ., et al. (2000). ACAPs are arf6 GTPase-activating proteins that function in the cell periphery. J Cell Biol, 151, 627–638.
20.
JonesP.A. (2012). Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet, 13, 484–492.
21.
KahnR.A., CherfilsJ., EliasM., LoveringR.C., MunroS., and SchurmannA. (2006). Nomenclature for the human Arf family of GTP-binding proteins: ARF, ARL, and SAR proteins. J Cell Biol, 172, 645–650.
22.
KlauschenF., MüllerK.R., BinderA., BockmayrM., HägeleM., SeegererP., et al. (2018). Scoring of tumor-infiltrating lymphocytes: from visual estimation to machine learning. Semin Cancer Biol, 52, 151–157.
23.
LheureuxS., BraunsteinM., and OzaA.M. (2019). Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin, 69, 280–304.
24.
LiB., SeversonE., PignonJ.C., ZhaoH., LiT., NovakJ., et al. (2016). Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol 17,174.
25.
LiJ., and HsuV.W. (2015). An ACAP1 coat complex acting in endocytic recycling. Methods Cell Biol, 130, 81–99.
26.
LiT., FanJ., WangB., TraughN., ChenQ., LiuJ.S., et al. (2017). TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res, 77, e108–e110.
27.
LuoR., ReedC.E., SloadJ.A., WordemanL., RandazzoP.A., and ChenP.W. (2019). Arf GAPs and molecular motors. Small GTPases, 10, 196–209.
28.
LytleN.K., BarberA.G., and ReyaT. (2018). Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer, 18, 669–680.
29.
MaZ., NieZ., LuoR., CasanovaJ.E., and RavichandranK.S. (2007). Regulation of Arf6 and ACAP1 signaling by the PTB-domain-containing adaptor protein GULP. Curr Biol, 17, 722–727.
30.
MaccalliC., RasulK.I., ElawadM., and FerroneS. (2018). The role of cancer stem cells in the modulation of anti-tumor immune responses. Semin Cancer Biol, 53, 189–200.
31.
MaltaT.M., SokolovA., GentlesA.J., BurzykowskiT., PoissonL., WeinsteinJ.N., et al. (2018). Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell, 173, 338–354.
32.
MirandaA., HamiltonP.T., ZhangA.W., PattnaikS., BechtE., MezheyeuskiA., et al. (2019). Cancer stemness, intratumoral heterogeneity, and immune response across cancers. Proc Natl Acad Sci U S A, 116, 9020–9029.
33.
MoothaV.K., LindgrenC.M., ErikssonK.F., SubramanianA., SihagS., LeharJ., et al. (2003). PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet, 34, 267–373.
34.
PanS., ZhanY., ChenX., WuB., and LiuB. (2019). Bladder cancer exhibiting high immune infiltration shows the lowest response rate to immune checkpoint inhibitors. Front Oncol 9,1101.
35.
PriceS.R., NightingaleM., TsaiS.C., WilliamsonK.C., AdamikR., ChenH.C., et al. (1988). Guanine nucleotide-binding proteins that enhance choleragen ADP-ribosyltransferase activity: nucleotide and deduced amino acid sequence of an ADP-ribosylation factor cDNA. Proc Natl Acad Sci U S A, 85, 5488–5491.
36.
RuB., WongC.N., TongY., ZhongJ.Y., ZhongS., WuW.C., et al. (2019). TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics, 35, 4200–4202.
37.
StrickerR., and ReiserG. (2014). Functions of the neuron-specific protein ADAP1 (centaurin-α1) in neuronal differentiation and neurodegenerative diseases, with an overview of structural and biochemical properties of ADAP1. Biol Chem, 395, 1321–1340.
38.
SubramanianA., TamayoP., MoothaV.K., MukherjeeS., EbertB.L., GilletteM.A., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 102, 15545–15550.
39.
SztulE., ChenP.W., CasanovaJ.E., CherfilsJ., DacksJ.B., LambrightD.G., et al. (2019). ARF GTPases and their GEFs and GAPs: concepts and challenges. Mol Biol Cell, 30, 1249–1271.
40.
Van AckerT., TavernierJ., and PeelmanF. (2019). The small GTPase Arf6: an overview of its mechanisms of action and of its role in Host-Pathogen interactions and innate immunity. Int J Mol Sci 20,2209.
41.
van de LeemputJ., BolesN.C., KiehlT.R., CorneoB., LedermanP., MenonV., et al. (2014). CORTECON: a temporal transcriptome analysis of in vitro human cerebral cortex development from human embryonic stem cells. Neuron, 83, 51–68.
42.
VasaikarS.V., StraubP., WangJ., and ZhangB. (2018). LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res, 46, D956–D963.
43.
VitaliT., Girald-BerlingeriS., RandazzoP.A., and ChenP.W. (2019). Arf GAPs: a family of proteins with disparate functions that converge on a common structure, the integrin adhesion complex. Small GTPases, 10, 280–288.
44.
WuC., ThalhamerT., FrancaR.F., XiaoS., WangC., HottaC., et al. (2014). Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity, 41, 270–282.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
